Landscapes / Targets
JAK1
9 drugs act on JAK1, in 53 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs9
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Janus kinase inhibitor |
Approved in the EU | 20 Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 20 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa (HS), NonSegmental Vitiligo and 2 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
AbbVie · Public ABBV |
Approved | Nov 2026soonPhase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Rheumatoid Arthritis and 13 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | 11 Dec 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 11 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis and 2 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved in China | Dec 2026Phase 1/2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Myelofibrosis, Chronic Graft Versus Host Disease and 1 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Pfizer · Public PFE |
Approved | 2 May 2027Phase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 2 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Eczema | ||||
| Open drug page | |||||
JAK inhibitor |
Approved in the EU | Jun 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Axial Spondyloarthritis, Ulcerative Colitis and 2 more | ||||
| Open drug page | |||||
JAK inhibitor |
Approved in Japan | 30 Nov 2027Phase 4 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Nov 2027 · Phase 4 trial completes | ||||
| Also tested for | Ulcerative Colitis | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Priovant Therapeutics +1 · Public PFE |
Approved | 31 Dec 2028Phase 2/3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 31 Dec 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Cutaneous Sarcoidosis, Lichen Planopilaris | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 1/2 | Nov 2026soonPhase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Leukemia, Myeloid, Acute, Refractory AML and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 9 of 9 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026